Trial

NCT01996098

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sun Yat-sen University
Collaborators
Condition
Lung Cancer
Intervention
6-month Icotinib
Why stopped
Slow accural.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-05